A new study by Dr Michael Law et al. of the University of British Columbia in Vancouver, Canada, published in the Archives of Internal Medicine of 23 November 2009, suggests that US direct-to-consumer advertising (DTCA) for a top-selling drug had no effect on prescribing rates, but led to a major rise in the drug’s price. Use of Bristol-Myers Squibb/sanofi-aventis’ blood-thinner Plavix (clopidogrel), which first appeared on the market in 1998, did not increase as a result of the consumer advertising campaign for it, which began in 2001. However, a “sudden and sustained increase” in the drug’s price after the advertisements commenced cost 27 state Medicaid programmes an additional US$207 million in pharmacy expenditures during 2001–2005, say the authors.
- Home
-
Generics
News
- FDA approves generic teriparatide and levetiracetam
- US generics launch and approval for Dr Reddy’s and Lupin
- Five Chinese companies join UN’s MPP for Covid-19 medicines
- South Korean companies to make generic Bridion and COVID-19 drugs
Research
- Generic medications in the Lebanese community: understanding and public perception
- Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study
- Reshaping landscape of Japanese generics market – uncertain future of universal health insurance
- Impact of e-bidding procurement on generic omeprazole injection prices in Thailand
-
Biosimilars
News
- China approves first denosumab copy biological Maiweijian
- EMA recommends approval of first denosumab biosimilar Jubbonti and Wyost
- First denosumab biosimilars approved in Canada and the US
- Dr Reddy's launches bevacizumab biosimilar Versavo in the UK
Research
- Topline results for Polpharma Biologics’ vedolizumab biosimilar candidate
- Comparing biosimilar adoption: Medicare Advantage versus traditional Medicare
- Questioning the need for ethnic sensitivity assessments for biosimilar monoclonal antibodies
- ANVISA's role in biosimilar medicine regulation and innovation promotion
- MORE EDITORIAL SECTIONS
- Search
Comments (0)
Post your comment